OBEZİTE VE İLAÇ FARMAKOLOJİSİ

Yazarlar

Mahmut Özdemir

Özet

Bu çalışma, obezitenin fizyolojik değişiklikler aracılığıyla ilaçların farmakokinetik (FK) ve farmakodinamik (FD) parametreleri üzerindeki etkilerini incelemektedir. Dünya Sağlık Örgütü verilerine göre obezite prevalansı küresel ölçekte hızla artmakta, tip 2 diyabet, kardiyovasküler hastalıklar ve astım gibi kronik rahatsızlık risklerini yükseltmektedir. Obezitede artan kan hacmi, kalp debisi ve mide boşalma hızı gibi değişimler ilaç emilimini, dağılımını ve eliminasyonunu etkiler. Özellikle sanal dağılım hacmi (Vs) yağ dokusunun artışından en çok etkilenen parametredir. Lipofilik ilaçlar yağ dokusuna daha fazla dağılma eğilimi gösterirken, hidrofilik ilaçların dağılımı sınırlı kalabilir. Bu nedenle, toplam vücut ağırlığına (TVA) dayalı dozlama obez bireylerde toksisite riskine yol açabileceğinden; ideal vücut ağırlığı (İVA), yağsız vücut ağırlığı (YVA) ve düzeltilmiş vücut ağırlığı (DVA) gibi vücut boyutu tanımlayıcılarının kullanımı önem taşır. Metabolizma tarafında CYP2E1 ve Faz II enzim aktiviteleri artarken CYP3A4 aktivitesinin azaldığı bildirilmiştir. Glomerüler filtrasyon hızı (GFH) ve renal klirens değişiklikleri ise renal yolla atılan ilaçların eliminasyonunu etkilemektedir. Sonuç olarak, obez hastalarda tek bir vücut tanımlayıcısı yerine ilacın fizikokimyasal özelliklerine uygun kişiselleştirilmiş doz ayarlamaları yapılmalı, terapötik ilaç izlemi uygulanmalı ve ilaç geliştirme süreçlerine obez popülasyonlar da dahil edilmelidir.

Referanslar

TUİK, Basın odası haberleri. Sayı, 15/2020, 11 Haziran 2020.

https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight 18 /03/2021

Haslam DW, James WPT, Obesity. Lancet, 2005; 366, 1197–209.

Stone AA, Broderick JE, Obesity and pain are associated in the United States. Obesity. 2012; 20,1491–95.

McCarthy LH, Bigal ME, Katz M, Chronic pain and obesity in elderly people: results from the Einstein aging study. J. Am. Geriatr. Soc. 2009; 57:115–19.

Choban PS, Heckler R, Burge JC, Increased incidence of nosocomial infections in obese surgical patients. Am. Surg. 1995; 61:1001–5.

Huttunen R, Karppelin M, Syrjanen J, Obesity and nosocomial infections. J. Hosp. Infect. 2013; 85:8–16.

Black MH, Zhou H, Takayanagi M, Increased asthma risk and asthmarelated health care complications associated with childhood obesity. Am. J. Epidemiol. 2013; 178:1120–28 .

Forno E, Lescher R, Strunk R, Decreased response to inhaled steroids in overweight and obese asthmatic children. J. Allergy Clin. Immunol. 2011; 127:741–49.

Gelelete CB, Pereira SH, Azevedo AM, et al. Overweight as a prognostic factor in children with acute lymphoblastic leukemia. Obesity 2011; 19:1908–11.

Knibbe CAJ, Brill MJE, Rongen AV, et al. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015; 55:149-67.

Blouin RA, Warren GW, Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1-7

Wellen KE, Hotamisligil GS, Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 2003;112:1785–1788.

Reilly SM,Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nature Rev Endocrin.2017; 13(11):633–643. .

Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011;121, 2111–2117

Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010; 72, 219–246

Cardoso-Júnior A, Coelho LGV, Savassi-Rocha PR, et al. Gastric emptying of solids and semisolids in morbidly obese and non-obese subjects: an assessment using the 13C-octanoic acid and 13C-acetic acid breath tests. Obes. Surg. 2007;17:236–241.

Teixeira TFS, Souza NCS, Chiarello PG, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin. Nutr. 2012;31:735–740.

Xing J, Chen JDZ, Alterations of gastrointestinal motility in obesity. Obes. Res. 2004;12:1723– 1732.

Alexander JK, Dennis EW, Smith WG, et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc. Res. Cent. Bull., 1962;1:39–44.

Lemmens HJM, Bernstein DP, Brodsky JB, Estimating blood volume in obese and morbidly obese patients. Obes. Surg. 2006;16:773–776.

Herrera MF, Deitel M, Cardiac function in massively obese patients and the effect of weight loss. Can. J. Surg. 1991;34:431–434.

Stelfox HT, Ahmed SB, Ribeiro RA, et al. Hemodynamic monitoring in obese patients: The impact of body mass index on cardiac output and stroke volume. Critical Care Medicine, 2006; 34(4): 1243–1246.

Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg. 2005;15:310–315.

Farrell GC, Teoh NC, Mccuskey RS, Hepatic microcirculation in fatty liver disease. Anat. Rec. Adv. Integr. Anat. Evol. Biol. 2008; 291: 684-692.

Benedek IH, Fiske WD, Griffen WO, et al. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br. J. Clin. Pharmacol. 1983;16:751–754.

Cheymol G, Poirier JM, Barre J, et al. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J. Clin. Pharmacol. 1987;27:874–879

Jones RL, Nzekwu MMU, The effecst of body mass index on lung volumes. Chest. 2006; 130:827-833.

Salome MS, King GG, Berend N, Physiology of obesity and effects on lung function. J Apply Physiol. 2010;108:206-211.

Schumann R, Pulmonary physiology of the morbidly obese and the effects of anesthesia. Inter Anesthesiology Clinics. 2013;51(3):41-51.

Costa D, Barbalho MC, Soares, GP, et al. The impact of obesity on pulmonary function in adult women. Clinics., 2008;63(6):719-724.

Beuther DA, Sutherland ER, Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175:661–666.

Chen YC, Dong GH, Lin KC, et al. Gender difference of childhood overweight and obesity in predicting the risk of incident asthma: a systematic review and meta-analysis. Obes Rev. 2013;14:222–231.

Rönmark E, Andersson C, Nyström L, et al. Obesity increases the risk of incident asthma among adults. Eur Respir J. 2005;25:282–288

Schachter LM, Peat JK, Salome CM, Asthma and atopy in overweight children. Thorax. 2003; 58: 1031–1035.

Schachter LM, Salome CM, Peat, JK, et al. Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax.2001;56:4–8.

Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000; 278: F817–22.

Anastasio P, Spitali L, Frangiosa A, et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis. 2000; 35: 1144–8.

Wuerzner G, Bochud M, Giusti V, et al. Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. Obes Facts. 2011; 4:238–243

Soares AA, Prates AB, Weinert LS, et al. Reference values for glome-rular filtration rate in healthy Brazilian adults. BMC Nephrol. 2013; 14:54

Ribstein J, du Cailar G, Mimran A, Combined renal effects of overweight and hypertension.Hypertens. (Dallas, Tex. 1979). 1995;26:610–615.

Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch. Intern. Med. 1986;146:1105–1109.

Kovesdy CP, Furth S, Zoccali C, et al. Obesity and kidney disease: Hidden consequences of the epidemic. Physiol. Int. 2017;104:1–14.

Roubenoff R, Kehayias JJ, The meaning and measurement of lean body mass. Nutr Rev. 1991;49:163-75.

Hanley MJ, Abertnethy DR, Greenblatt DJ, Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71-87.

Sankaralingam S, Kim RB, Padva IRS, The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control.Canadian Journal of cardiology, 2015;31:167-176.

Kjellberg J, Reizenstein P, Body composition in obesity. Acta Med Scand. 1970;188:161-9.

Green B, Duffull S, Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther. 2002;72:743-4.

Green B, Duffull SB, What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119-33.

Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet. 2004;43:1167-78.

Tosetti C, Corinaldesi R, Stanghellini V,et al. Gastric emptying of solids in morbid obesity. Int J Obes Relat Metab Disord. 1996;20:200–5.

Wisen O, Hellstrom PM, Gastrointestinal motility in obesity. J Intern Med. 1995;237:411–8.

Dubois A, Obesity and gastric emptying. Gastroenterology. 1983; 84: 875–6

Wright RA, Krinsky S, Fleeman C, et al. Gastric emptying and obesity. Gastroenterology. 1983;84:747–51.

Zahorska-Markiewicz B, Jonderko K, Lelek A, et al. Gastric emptying in obesity. Hum Nutr Clin Nutr. 1986;40:309–13.

Basilisco G, Camboni G, Bozzani A, et al. Orocecal transit delay in obese patients. Dig Dis Sci, 1989;34:509–12.

Wisen O, Johansson C, Gastrointestinal function in obesity: motility, secretion, and absorption following a liquid test meal. Metabolism, 1992;41:390–5.

Lesser GT, Deutsch S, Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol. 1967;23:621–30

Sanderink GJ, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. 2002; 72, 308–318.

Clauson PG & Linde B, Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care. 1995;18, 986–991.

Rassard PAB, Gagnon-Auger M, du Souich P, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33:0–5.

Flechner SM, Kolbeinsson ME, Tam J, et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation. 1989 :47: 806–810.

Cheymol G, Weissenburger J, Poirier JM, et al. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br. J. Clin. Pharmacol. 1995; 39, 684–687.

Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61, 27–35.

Bowman SL, Hudson SA, Simpson G, et all. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol. 1986;21:529–32

Chan CCW, Ng EHY, Chan MMY, et al. Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women. Hum. Reprod. 2003;18:2294–2297.

Edelman AB, Cherala G, Stanczyk FZ, Metabolism and pharmacokinetics of contraceptive steroids in obesewomen: a review. Contraception. 2010;82:314-323.

Jain R, Chung SM, Jain L, et all. Implications of Obesity for Drug Therapy: Limitations and Challenges. Clin.Pharmacol. Ther. 2011;90(1):77-89.doi:10.1838/clpt.2011.104.

Brill MJE, Diepstraten J, Van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin. Pharmacokinet. 2012;51:277–304.

Karlsson MO, Bredberg U, Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharm. Res. 1989;6:817–821.

Bredberg U, Karlsson MO, Borgström LA, Comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin.Pharmacol. Ther. 1992;52:239-248.

Brill MJE, Van Rongen A, Houwink API, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: A comparison with healthy volunteers. Clin. Pharmacokinet. 2014;53:931–941.

Berezhkovskiy LM, On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J. Pharm. Sci. 2011;100:2482–2497.

Hinderling PH, Red blood cells: a neglected compartment in phar-macokinetics and pharmacodynamics. Pharmacol. Rev. 1997;49.279-295.

Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. J. Clin. Pharmacol. 1983;23:369–376.

Davis RL, Quenzer RW, Bozigian HP, et al. Pharmacokinetics of ranitidine in morbidly obese women. DICP. 1990;24:1040-1043.

Van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin. Pharmacokinet. 2011;50:739–750.

Abernethy DR, Greenblatt DJ, Smith TW, Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am. Heart J. 1981;102:740–744.

Adane ED, Herald M, Koura F, Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed staphylococcus aureus infections. Pharmacotherapy. 2015;35:127–139.

Brill MJE, Houwink API, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical Accepted Manuscript 25 microdialysis. J. Antimicrob. Chemother. 2014;69:715–723.

Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob. Agents Chemother., 2007;51:2741–2747.

Abernethy DR, Greenblatt DJ, Divoll M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin. Pharmacokinet. 2017;9:177–183.

Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J. Lab. Clin. Med. 1983;101:873–880.

Hollenstein UM, Brunner M, Schmid R, et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int. J. Obes. Relat. Metab. Disord. 2001;25:354–358.

Barbour A, Schmidt S, Rout WR, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int. J. Antimicrob. Agents. 2009;34:231–235.

Dong D, Peng X, Liu J, et al. Morbid obesity alters both pharmacokinetics and pharmacodynamics of propofol: Dosing recommendation for anesthesia induction. Drug Metab. Dispos. 2016;44:1579–1583.

Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic Accepted Manuscript 26 meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst. Pharmacol. 2013;2:e73. doi:10.1038/psp. 2013.47

Ingrande, J., Brodsky, J. B., Lemmens, H. J. M., Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth. Analg, 2011;113:57–62.

Kolwankar D, Vuppalanchi R, Ethell B, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin. Gastroenterol. Hepatol., 2007;5:388– 393.

Ghose R, Omoluabi O, Gandhi A, et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 2011;89:57–64.

Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab. Dispos. 2015;43:1484–1490.

Adane ED, van Ramshorst B, Hazebroek EJ, Darwich AS, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32(12):3927–36.

Lieber CS.CYP2E1:from ASH to NASH. Hepatol. Res. 2004;28,1–11.

Buechler C. & Weiss, T.S. Does hepatic steatosis affect drug metabo-lizing enzymes in the liver? Curr. Drug Metab. 2011;12, 24–34.

Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003;38:428–435.

Van Rongen A, Välitalo PAJ, Peeters MYM, et al. Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of acetaminophen. Clin. Pharmacokinet. 2016;55(7):833-847.

Caraco Y, Zylber-Katz E, Berry EM, et al. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int. J. Obes. Relat. Metab. Disord. 1995;19:234–239

Kotlyar M & Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int. J. Clin. Pharmacol. Ther. 1999;37, 8–19.

De Hoogd S, Välitalo PAJ, Dahan A, et al. Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide. Clin. Pharmacokinet. 2017;1–11.

Ferslew BC, Johnston CK, Tsakalozou E, et al. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin. Pharmacol. Ther. 2015;97:419– 427.

Fisher CD, Lickteig AJ, Augustine LM, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol. 2009;613:119–127.

Ali I, Slizgi JR, Kaullen JD, et al. Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate. Clin. Pharmacol. Ther. 2017; DOI:10.1002/cpt.997.

Smit C, De Hoogd S, Brüggemann RJM, et all. Obesity and drug pharmacology: a review of the infuence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14:275–85.DOI: 10.1080/17425255.2018.1440287.

Anastasio P, et al. Glomerular filtration rate in severely overweight normotensive humans. Am. J. Kidney Dis. 2000;35, 1144–1148.

Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 2001;12, 1211–1217.

Janmahasatian S, Duffull SB, Chagnac A, et al. Lean body mass normalizes the effect of obesity on renal function. Br. J. Clin. Pharmacol. 2008;65, 964–95.

Naumnik B, Mysliwiec M. Renal consequences of obesity. Med. Sci. Monit. 2010;16, RA163–RA170.

Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am. J. Heal. Syst. Pharm. 2009;66:642–648.

Bauer LA, Edwards WAD, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur. J. Clin. Pharmacol. 1983;24:643–647.

Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob. Agents Chemother. 2016;60:6550–6557.

Chairat K, Jittamala P, Hanpithakpong W, et al. Population phar-macokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br. J. Clin. Pharmacol. 2016;81:1103–1112.

Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci. 1982; 71: 942-4.

Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int. J. Obes. 2013;37:333–340.

Varin F, Ducharme J, Theoret Y, et al. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin. Pharmacol. Ther. 1990;48:18–25.

Van Kralingen S, Van De Garde EMW, Knibbe CAJ, et al. Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients. Br. J. Clin. Pharmacol. 2011;71:34–40.

Derry CL, Kroboth PD, Pittenger AL, et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J. Clin. Psychopharmacol. 1995;15, 197–205.

Bonadonna RC, Groop L, Kraemer N, et al. Obesity and insulin resistance in humans:a dose-response study. Metab. Clin. Exp. 1990;39, 452–459.

Schmid C, Krayenbühl P. & Wiesli P. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes. Diabetologia. 2009;52, 2668–2669.

Blokhin IO, Lentz SR. Mechanisms of thromboss in obesity. Curr Opin Hematol , 2013; 20(5): 437-444.

Shin S, Harthan EF. Safety and efficacy of the use of institutional unfractioned heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. Blood Coagul Fibrinolysis 2015; 26(6): 655-660.

Floroff CK, Palm NM, Steinberg DH, et al. Higher maximum doses and infusion rate compared with standard unfractionated heparin therapy are associated with adequate anticoagulation without increased bleeding in both obese and non-obese patients with cardiovascular indication. Pharmacotherapy 2017; 37(4): 393-400

Trovati M, Mularoni EM, Burzacca S, et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes. 1995;44:1318-22.

Schmieder RE, Gatzka C, Schachinger H et al. Obesity as a determinant for response to antihypertensive treatment. Br Med J 1993; 307: 537-540.

Yayınlanan

11 Mayıs 2021

Lisans

Lisans